Modification and uptake of a cisplatin carbonato complex by Jurkat cells

Molecular Pharmacology

Volumn 70, Issue 1, 2006, Pages 348-355

  Centerwall, Corey R ^a   Tacka, Kirk A ^a,c   Kerwood, Deborah J ^a   Goodisman, Jerry ^a   Toms, Bonnie B ^b   Dubowy, Ronald L ^b   Dabrowiak, James C ^a  

^a SYRACUSE UNIVERSITY   (United States)

^b STATE UNIVERSITY OF NEW YORK   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON; CISPLATIN DERIVATIVE; GENOMIC DNA;

AREA UNDER THE CURVE; ARTICLE; CELL CULTURE; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG DETERMINATION; DRUG UPTAKE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MASS SPECTROMETRY; MOLECULAR WEIGHT; PRIORITY JOURNAL; QUANTUM CHEMISTRY;

BIOLOGICAL TRANSPORT; CARBONATES; CISPLATIN; DNA ADDUCTS; DNA, NEOPLASM; HUMANS; JURKAT CELLS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; PLATINUM; TIME FACTORS;

EID: 33745262587     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.023184     Document Type: Article

References (26)

1. Acharya AN, Das AC, and Dash AC (2004) Carbonato complexes: models for carbonic anhydrase. Adv Inorg Chem 55:127-199.
2. Allison DC and Ridolpho P (1980) Use of trypan blue assay to measure the deoxyribonucleic acid content and radioactive labeling of viable cells. J Histochem Cytochem 28:700-703.
3. Berners-Price SJ and Appleton TG (2000) The chemistry of cisplatin in aqueous solution, in Platinum-Based Drugs in Cancer Therapy (Kelland LR and Farrell N eds) pp 3-35, Humana Press Inc., Totowa, NJ.
4. Binter A, Goodisman J, and Dabrowiak JC (2006) Formation of monofunctional cisplatin-DNA adducts in carbonate buffer. J Inorg Biochem, in press. (DOI:10.1016/j.jinorgbio.2006.01.040)
5. Boulikas T and Vougiouka M (2004) Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncol Rep 11:559-595.
6. Brabec V and Kasparkova J (2005) Modifications of DNA by platinum complexes. Relation to resistance of tumors to platinum antitumor drugs. Drug Resist Updat 8:131-146.
7. Centerwall CR, Goodisman J, Kerwood DJ, and Dabrowiak JC (2005) Cisplatin carbonato complexes. Implications for uptake, antitumor properties and toxicity. J Am Chem Soc 127:12768-12769.
8. Di Pasqua AJ, Goodisman J, Kerwood DJ, Toms BB, Dubowy RL, and Dabrowiak JC (2006) Activation of carboplatin by carbonate. Chem Res Toxicol 19:139-149.
9. Eastman A (1999) Mechanism of action of cisplatin: from adducts to apoptosis, in Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug (Lippert B ed) pp 111-134, Weinheim, Wiley-VCH, Zurich.
10. El-Khateeb M, Appleton TG, Gahan LR, Charles BG, Berners-Price SJ, and Bolton A (1999) Reaction of cisplatin hydrolytes with methionine, cysteine and plasma ultrafiltrate studied by a combination of HPLC and NMR techniques. J Inorg Biochem 77:13-21.
11. Gately DP and Howell SB (1993) Cellular accumulation of the anticancer drug cisplatin: a review. Br J Cancer 67:1170-1176.
12. Ghezzi A, Aceto M, Cassino C, Gabano E, and Osella D (2004) Uptake of antitumor platinum (II)-complexes by cancer cell, assayed by inductively coupled plasma mass spectrometry (ICP-MS). J Inorg Biochem 98:73-78.
13. Jennerwein M and Andrews PA (1994) Drug Accumulation and DNA platination in cells exposed to aquated cisplatin species. Cancer Lett 81:215-220.
14. Johnson SW, Shen DW, Pastan I, Gottesman MM, and Hamilton TC (1996) Crossresistance, cisplatin accumulation and platinum-DNA adduct formation and removal in cisplatin-sensitive and -resistant human hepatoma cell lines. Exp Cell Res 226:133-139.
15. Kartalou M and Essigmann JM (2001) Mechanism of resistance to cisplatin. Mutat Res 478:23-43.
16. Lindauer E and Holler E (1996) Cellular distribution and cellular reactivity of platinum (II) complexes. Biochem Pharmacol 52:7-14.
17. Mann SC, Andrews PA, and Howell SB (1990) Short-term cis- diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. Cancer Chemother Pharmacol 25:236-240.
18. Miller SE and House DA (1990) The hydrolysis products of cis-dichlorodiammineplatinum(II) 3. Hydrolysis kinetics at physiological pH. Inorg Chim Acta 173:53-60.
19. Palmer DA and van Eldik R (1983) The chemistry of metal carbonato and carbon dioxide complexes. Chem Rev 83:651-731.
20. Pereira-Maia E and Garnier-Suillerot A (2003) Impaired hydrolysis of cisplatin derivatives to aquated species prevents energy-dependent uptake in GLC4 cells resistant to cisplatin. J Biol Inorg Chem 8:626-634.
21. Rosenberg B (1971) Some biological effects of platinum compounds. Plat Met Rev 15:42-51.
22. Sadowitz PD, Hubbard BA, Dabrowiak JC, Goodisman J, Tacka KA, Aktas MK, Cunningham MJ, Dubowy RL, and Souid K-A (2002) Kinetics of cisplatin binding to cellular DNA and modulation by thiol-blocking agents and thiol drugs. Drug Metab Dispos 30:183-190.
23. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis for resistance. Oncogene 22:7265-7279.
24. Stocker FW and Dietrich G (1996) eds, Concise Encyclopedia of Biology (Scott TA, rev, trans), Walter de Gruyter, New York.
25. Tacka KA, Szalda D, Souid A-K, Goodisman J, and Dabrowiak JC (2004) Experimental and theoretical studies on the pharmacodynamics of cisplatin in Jurkat cells. Chem Res Toxicol 17:1434-1444.
26. Wang D and Lippard SJ (2005) Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4:307-320.